CD274 and neoplasm: As the definitions of positive and negative tumor PD‐L1 expression as well as the laboratory methods used to ascertain them were not homogenous across the two PD‐1 trials (Nivolumab: at least 5% of tumor cells with PD‐L1 at any intensity at the membrane; Pembrolizumab: >1% tumor cells with membranous PD‐L1 expression), we accepted the trials’ original cutoffs.